Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

MyNCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1948 2
1950 1
1951 6
1952 11
1953 4
1954 6
1955 5
1956 9
1957 11
1958 10
1959 9
1960 9
1961 12
1962 23
1964 1
1965 12
1966 23
1967 25
1968 24
1969 30
1970 17
1971 26
1972 29
1973 27
1974 25
1975 34
1976 28
1977 33
1978 34
1979 45
1980 33
1981 32
1982 39
1983 44
1984 57
1985 63
1986 67
1987 75
1988 82
1989 105
1990 104
1991 99
1992 104
1993 83
1994 117
1995 165
1996 135
1997 135
1998 124
1999 158
2000 158
2001 195
2002 246
2003 290
2004 288
2005 353
2006 414
2007 500
2008 452
2009 515
2010 570
2011 674
2012 679
2013 732
2014 711
2015 754
2016 832
2017 752
2018 731
2019 341
2020 15
Text availability
Article attribute
Article type
Publication date

Search Results

11,285 results
Results by year
Filters applied: . Clear all
Page 1
Multiple myeloma.
Röllig C, et al. Lancet 2015 - Review. PMID 25540889
Multiple myeloma is a malignant disease characterised by proliferation of clonal plasma cells in the bone marrow and typically accompanied by the secretion of monoclonal immunoglobulins that are detectable in the serum or urine. Increased understanding of the microenvironmental interactions between malignant plasma cells and the bone marrow niche, and their role in disease progression and acquisition of therapy resistance, has helped the development of novel therapeutic drugs for use in combination with cytostatic therapy. ...
Multiple myeloma is a malignant disease characterised by proliferation of clonal plasma cells in the bone marrow and typically
Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group.
Sonneveld P, et al. Blood 2016. PMID 27002115 Free PMC article.
The International Myeloma Working Group consensus updates the definition for high-risk (HR) multiple myeloma based on cytogenetics Several cytogenetic abnormalities such as t(4;14), del(17/17p), t(14;16), t(14;20), nonhyperdiploidy, and gain(1q) were identified that confer poor prognosis. ...Patients with multiple adverse cytogenetic abnormalities do not benefit from these agents. FISH data are implemented in the revised International Staging System for risk stratification....
The International Myeloma Working Group consensus updates the definition for high-risk (HR) multiple myeloma based on c …
Frontline therapy of multiple myeloma.
Moreau P, et al. Blood 2015 - Review. PMID 25838345
In the past decade, one of the major advances in the management of patients with symptomatic newly diagnosed multiple myeloma has been the introduction of novel agents, thalidomide, bortezomib, and lenalidomide, as part of frontline treatment in both transplant and nontransplant candidates. ...This article focuses on more recent frontline therapeutic approaches both in older patients, not eligible for high-dose therapy and autologous stem cell transplantation (ASCT), and in younger patients eligible for early ASCT....
In the past decade, one of the major advances in the management of patients with symptomatic newly diagnosed multiple myeloma
Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines 2013.
Mikhael JR, et al. Mayo Clin Proc 2013. PMID 23541011
Multiple myeloma remains an incurable neoplasm of plasma cells that affects more than 20,000 people annually in the United States. ...A risk-adapted approach provides optimal therapy to patients, ensuring intense therapy for aggressive disease and minimizing toxic effects, providing sufficient but less intense therapy for low-risk disease. ...
Multiple myeloma remains an incurable neoplasm of plasma cells that affects more than 20,000 people annually in the United Sta
Second primary malignancies in multiple myeloma: an overview and IMWG consensus.
Musto P, et al. Ann Oncol 2017 - Review. PMID 27864218 Free article.
BACKGROUND: Therapeutic advancements following the introduction of autologous stem cell transplantation and 'novel' agents have significantly improved clinical outcomes for patients with multiple myeloma (MM). ...DESIGN: A Panel of International Myeloma Working Group members reviewed the most relevant data published in the literature as full papers, or presented at meetings of the American Society of Clinical Oncology, American Society of Hematology, European Hematology Association, or International Myeloma Workshops, up to June 2016. ...
BACKGROUND: Therapeutic advancements following the introduction of autologous stem cell transplantation and 'novel' agents have significantl …
[Multiple myeloma : What has been confirmed in therapy?].
Baertsch MA and Goldschmidt H. Internist (Berl) 2017 - Review. PMID 29098319 German.
Multiple myeloma (MM) is a malignancy of terminally differentiated B cells/plasma cells and is primarily located in the bone marrow. Symptomatic multiple myeloma typically presents with osteolyses, anemia, reduced renal function, and/or hypercalcemia. In the case of such MM-related end organ damage, urgent systemic treatment is indicated. ...
Multiple myeloma (MM) is a malignancy of terminally differentiated B cells/plasma cells and is primarily located in the bone m
The multiple myeloma treatment landscape: international guideline recommendations and clinical practice in Europe.
Cavo M, et al. Expert Rev Hematol 2018 - Review. PMID 29415570
Guidelines provide recommendations on the management of multiple myeloma (MM), but there are no standard algorithms for the choice and sequencing of treatments. ...
Guidelines provide recommendations on the management of multiple myeloma (MM), but there are no standard algorithms for the ch …
Current management and emerging treatment strategies for multiple myeloma.
Lei M, et al. Rinsho Ketsueki 2019 - Review. PMID 31597850
Multiple myeloma is a malignant plasma cell neoplasm that is incurable despite significant progress in treatment over the past several decades. ...The addition of new treatment options and combinations has added complexity in treatment selection for myeloma patients. The current strategy for newly diagnosed myeloma involves induction, consolidation, and maintenance therapy. ...
Multiple myeloma is a malignant plasma cell neoplasm that is incurable despite significant progress in treatment over the past
Nanotherapeutics for multiple myeloma.
Zheleznyak A, et al. Wiley Interdiscip Rev Nanomed Nanobiotechnol 2018 - Review. PMID 29701006 Free PMC article.
Multiple myeloma (MM) is an age-related hematological malignancy with an estimated 30,000 new cases and 13,000 deaths per year. ...As such, there remains a crucial need to develop advanced drug delivery systems that can navigate the complex BMM and effectively reach the myeloma cells. ...
Multiple myeloma (MM) is an age-related hematological malignancy with an estimated 30,000 new cases and 13,000 deaths per year
Novel Treatments for Multiple Myeloma: What Role Do They Have in Older Adults?
Mian HS and Wildes TM. Drugs Aging 2018 - Review. PMID 29557059
Multiple myeloma is a malignant plasma cell disease, which typically affects older patients, with a median age at diagnosis of 70 years. ...Autologous stem-cell transplantation has been a standard part of therapy for myeloma patients for many years, first in younger patients and increasingly in older, and may still be considered in selected older patients with myeloma. ...
Multiple myeloma is a malignant plasma cell disease, which typically affects older patients, with a median age at diagnosis of
11,285 results
Jump to page
Feedback